Kjersti Flatmark - Concepedia

Author

Kjersti Flatmark

Also Known As

Flatmark, Kjersti, G Ferron, K Flatmark, K. Flatmark, Kjersti Flatmark, Kjersti Flatmark (76807), M D Evans, N S Fearnhead, Peritoneal Surface Oncology Group International (PSOGI), Nordic Peritoneal Oncology Group (NPOG), American Society for Peritoneal Surface Malignancy (ASPSM) and BIG-RENAPE Groups, S Feshtali

271

Publications

6.2K

Citations

H-Index

Concepts

All Affiliations

University of Oslo Oslo University Hospital Akershus University Hospital Norwegian Cancer Society Norwegian University of Science and Technology

About

Kjersti Flatmark is an author at University of Oslo specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	40	2K
2	Engineering	6	6	280
3	Health Sciences	4	4	240
4	Natural Sciences	3	3	292
5	Biochemistry	1	1	16

Kjersti Flatmark

100

Publications

4.9K

Citations

H-Index

Page 1

	Year	Citations
Laparoscopic Versus Open Resection for Colorectal Liver Metastases Åsmund Avdem Fretland, Vegar Johansen Dagenborg, Gudrun Maria Waaler Bjørnelv, Annals of Surgery	2017	666
MirGeneDB 2.0: the metazoan microRNA complement Bastian Fromm, Diana Domańska, Eirik Høye, Nucleic Acids Research BiologyBioinformaticsSystems BiologySmall Non-coding RnasNatural Sciences	2019	262
Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer Kristina Schee, Kjetil Boye, Torveig Weum Abrahamsen, BMC Cancer	2012	173
Deep Sequencing the MicroRNA Transcriptome in Colorectal Cancer Kristina Schee, Susanne Lorenz, Merete Molton Worren, PLoS ONE Tumor BiologyPrognostic BiomarkersOncologyEngineeringMedicine	2013	146
Matrix Metalloproteinases Participate in Osteosarcoma Invasion Kristin Bjørnland, Kjersti Flatmark, Solveig Pettersen, Journal of Surgical Research Bone Morphogenic ProteinMetalloproteinOsteosarcoma InvasionPathologyCell-matrix Interaction	2005	141
Prophylactic mesh at end‐colostomy construction reduces parastomal hernia rate: a randomized trial Jan Roland Lambrecht, Stein Gunnar Larsen, O Reiertsen, Colorectal Disease	2015	123
Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study Anne Hansen Ree, Svein Dueland, Sigurd Folkvord, The Lancet Oncology Radiation TherapyHistone Deacetylase InhibitorPelvic RadiationMedicineGastrointestinal Oncology	2010	122
B7‐H3 expression in colorectal cancer: Nuclear localization strongly predicts poor outcome in colon cancer Vibeke Anett Ingebrigtsen, Kjetil Boye, Christina Tekle, International Journal of Cancer Tumor BiologyRadiation OncologyPrognostic BiomarkersOncologyGastrointestinal Oncology	2012	119
Twelve colorectal cancer cell lines exhibit highly variable growth and metastatic capacities in an orthotopic model in nude mice Kjersti Flatmark, Gunhild M. Mælandsmo, Marita Martinsen, European Journal of Cancer OncologyMetastatic CapacitiesMedicineBiological MicroenvironmentsPathology	2004	118
Clinical Significance of Long Intergenic Noncoding RNA-p21 in Colorectal Cancer Haiyan Zhai, Andrew Fesler, Kristina Schee, Clinical Colorectal Cancer Tumor BiologyMedicinePathologyColorectal CancerCancer Genomics	2013	109

Page 1